252 related articles for article (PubMed ID: 19951720)
1. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720
[TBL] [Abstract][Full Text] [Related]
2. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
4. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
5. [Quantitative Prediction of Drug-Drug Interaction Caused by CYP Inhibition and Induction from In Vivo Data and Its Application in Daily Clinical Practices-Proposal for the Pharmacokinetic Interaction Significance Classification System (PISCS)].
Ohno Y
Yakugaku Zasshi; 2018; 138(3):337-345. PubMed ID: 29503426
[TBL] [Abstract][Full Text] [Related]
6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
7. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
Tornio A; Filppula AM; Backman JT
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
[TBL] [Abstract][Full Text] [Related]
8. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
9. Theoretical considerations on quantitative prediction of drug-drug interactions.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Drug Metab Pharmacokinet; 2010; 25(1):48-61. PubMed ID: 20208388
[TBL] [Abstract][Full Text] [Related]
10. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
11. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
13. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
15. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
17. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.
Mouly S; Meune C; Bergmann JF
Intensive Care Med; 2009 Mar; 35(3):417-29. PubMed ID: 19132343
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
20. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.
Almond LM; Yang J; Jamei M; Tucker GT; Rostami-Hodjegan A
Curr Drug Metab; 2009 May; 10(4):420-32. PubMed ID: 19519348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
